rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
Status:
Completed
Trial end date:
2016-09-03
Target enrollment:
Participant gender:
Summary
The primary research question is, in patients with short bowel syndrome requiring central
venous access device (CVAD) for long-term total parenteral nutrition, is once weekly
recombinant tissue plasminogen activator (rtPA) lock therapy more effective than routine care
using heparin flushes in reducing the incidence of line-associated thrombosis and infection.